BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27774779)

  • 1. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
    Maggi M; Wu FC; Jones TH; Jackson G; Behre HM; Hackett G; Martin-Morales A; Balercia G; Dobs AS; Arver ST; Maggio M; Cunningham GR; Isidori AM; Quinton R; Wheaton OA; Siami FS; Rosen RC;
    Int J Clin Pract; 2016 Oct; 70(10):843-852. PubMed ID: 27774779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
    Rosen RC; Wu FC; Behre HM; Roehrborn CG; Schröder FH; Siami FS; Martha JF; Finn JD; Araujo AB
    Aging Male; 2013 Mar; 16(1):1-7. PubMed ID: 23373674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events.
    Corona G; Rastrelli G; Maseroli E; Fralassi N; Sforza A; Forti G; Mannucci E; Maggi M
    Andrology; 2014 Sep; 2(5):741-7. PubMed ID: 25044637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
    Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
    JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
    Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
    Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
    Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
    Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
    Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
    BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
    Traish AM; Haider A; Haider KS; Doros G; Saad F
    J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy for late-onset hypogonadism.
    Cunningham GR
    Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-Art: a Review of Cardiovascular Effects of Testosterone Replacement Therapy in Adult Males.
    Elsherbiny A; Tricomi M; Bhatt D; Dandapantula HK
    Curr Cardiol Rep; 2017 Apr; 19(4):35. PubMed ID: 28361372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy.
    Rosen RC; Seftel AD; Ruff DD; Muram D
    Am J Mens Health; 2018 May; 12(3):567-574. PubMed ID: 26819183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-life onset hypogonadism: a review.
    Bassil N; Morley JE
    Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.